Company intelligence / Profile preview

Institute for Radioelements

Fleurus, Wallonia, Belgium

Ownership: Private
Employees: ~270
Development stage: Other

Overview

IRE is a world leader in commercial-scale production of radioisotopes (notably molybdenum-99, iodine-131, and gallium-68) for diagnostic and therapeutic use in nuclear medicine; its subsidiary IRE ELiT develops and commercializes radiopharmaceuticals for cancer imaging and therapy, including FDA- and EMA-approved gallium-68 generators.

Therapeutic areas: OncologyCardiovascularOther
Modalities: RadiopharmaceuticalRadiopharmaceutical precursorRadiopharmaceutical generator
Industry: Biotech

Partnerships

SCK CEN (Belgium's Nuclear Research Centre, for isotope production and residue processing)IBA (Belgium, radioisotope supply chain)CEA (France, irradiation partner)Grand Pharmaceutical (China, distribution of Ga-68 generators)Lantheus Medical Imaging (USA, Mo-99 supply agreement)

Beyond the preview

Go deeper on Institute for Radioelements.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Institute for Radioelements.

Explore the full profile